Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Diabetes in Developing Countries
Published in: International Journal of Diabetes in Developing Countries 3/2023

02-08-2022 | Obesity | Original Article

Evaluation of progression in metabolic parameters along with markers of subclinical inflammation and atherosclerosis among normoglycemic first degree relatives of type 2 diabetes mellitus patients

Authors: Deepak Kumar Dash, Swayamsidha Mangaraj, Arun Kumar Choudhury, Mamta Singh, Anoj Kumar Baliarsinha

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2023

Login to get access

Abstract

Background

The aim of this study is to assess for the change in progression of inflammatory, adiposity, and atherosclerotic markers in first degree relatives of type 2 diabetes mellitus patients.

Methods

Normal glucose tolerant (NGT) individuals (20–40 years) who had positive family history of T2DM (FHP) were enrolled in this prospective study based on ADA 2015 criteria. Age, sex, and BMI matched controls without any history of diabetes in their parents referred as family history negative (FHN) were taken for comparison. At baseline, detailed clinical assessment and requisite blood/imaging investigations were done. All the available subjects from the original cohort (FHN-32 and FHP-46) were studied after 2 years with recording of the clinical, biochemical and imaging parameters.

Results

A total of 64 cases (FHP) and 42 controls (FHN) were enrolled at baseline. FHP group had significantly higher hsCRP (p = 0.039) and cIMT (p = 0.003) than that of FHN group. No significant difference in the rate of conversion of NGT to prediabetes (using multiple criteria) was found after 2 years between the two groups. cIMT was increased significantly from baseline in FHP group than FHN group at the end of the study(0.02 ± 0.03 vs. 0.01 ± 0.02 mm, p = 0.002). But there was no significant difference for changes in glycemic status, lipid parameters, HOMA IR, hsCRP, and adiposity markers between the two groups at the end of the study.

Conclusion

Despite no significant differences in change in glycemic parameters or rates of conversion from NGT to pre diabetes, cIMT increased significantly in the normoglycemic offspring of T2DM subjects than those without history of T2DM in their parents.
Literature
1.
Kobberling J, Tillil H. Empirical risk figures for first-degree relatives of non-insulin dependent diabetics. In: Kobberling J, Tattersall R, editors. The genetics of diabetes mellitus. London: Academic Press; 1982. p. 201–9.
2.
Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.CrossRefPubMed
3.
Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycemia, insulin sensitivity and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215–21.CrossRefPubMedPubMedCentral
4.
Anjana RM, Rani CS, Deepa M, Pradeepa R, Sudha V, Nair HD, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians:10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES). Diabetes Care. 2015;38:1441–8.CrossRefPubMed
5.
Crook MA. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med. 2004;21:203–7.CrossRefPubMed
6.
Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003;92:18J–26J.CrossRefPubMed
7.
Nakanishi S, Yamane K, Kamel N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003;26:2754–7.CrossRefPubMed
8.
Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, at al. Low grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes 2003;52:1799–1805.
9.
Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45:633–8.CrossRefPubMed
10.
Kriketos AD, Greenfield JR, Peake PW, Furler SM, Denyer GS, Charlesworth JA, Campbell LV. Inflammation, insulin resistance, and adiposity. Diabetes Care. 2004;27:2033–40.CrossRefPubMed
11.
Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, for the AlkaMeSy Study Group. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920–2.CrossRefPubMedPubMedCentral
12.
Groop L, Forblom C, Lehtovirta M, Tuomi T, Karanko S, Nissen M, et al. Metabolic consequences of a family history of NIDDM (the Botnia Study). Diabetes. 1996;45:1585–93.CrossRefPubMed
13.
Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85:1–10.CrossRefPubMedPubMedCentral
14.
Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris prospective study, ten years later. Horm Metab Res. 1985;15:41–6.
15.
Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima media-thickness. A systematic review and meta analysis. Circulation. 2007;115:459–67.CrossRefPubMed
16.
Shaw JTE, Purdie DM, Neil HAW, Levy JC, Turner RC. The relative risk of hyperglycemia, obesity and dyslipidemia in the relatives of pts of type 2 diabetes mellitus. Diabetologia. 1999;42:24–7.CrossRefPubMed
17.
American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2015;38:S8–S16.CrossRef
18.
Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502.CrossRefPubMed
19.
20.
Stolk RP, Wink O, Zelissen PM, Meijer R, van Gils AP, Grobbee DE. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord. 2001;25:1346–51.CrossRefPubMed
21.
Dash DK, Choudhury AK, Singh M, Mangaraj S, Mohanty BK, Baliarsinha AK. Effect of parental history of diabetes on markers of inflammation, insulin resistance and atherosclerosis in first degree relatives of patients of type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2018;12(3):285–9.CrossRef
22.
Ahmad J, Ahmed F, Siddiqui MA, Hameed B, Ahmad I. Inflammation, insulin resistance and carotid IMT in first degree relatives of north Indian type 2 diabetic subjects. Diabetes Res Clin Pract. 2006;73:205–10.CrossRefPubMed
23.
Pannacciulli N, De Pergola G, Ciccone M, Rizzon P, Giorgino F, Giorgino R. Effect of family history of type 2 diabetes on the intima-media thickness of the common carotid artery in normal-weight, overweight, and obese glucose-tolerant young adults. Diabetes Care. 2003;26:1230–4.CrossRefPubMed
24.
Ustun I, Aydin Y, Arduc AA, Berker D, Ozuguz U, Yulmaz M, et al. Evaluation of atherosclerotic risk factors and carotid intima media thickness in healthy offspring of type 2 diabetic patients. Acta Endocrinol (1841-0987). 2010;6(2):211–27.
25.
Purnamasari D, Abdaly MS, Azizi MS, Wijaya IP, Nugroho P. Carotid intima media thickness among normoglycemia and normotension first degree relatives of type 2 diabetes mellitus. Vasc Health Risk Manag. 2019;15:101–7.CrossRefPubMedPubMedCentral
26.
Janghorbani M, Amini M. Progression to impaired glucose metabolism in first degree relatives of patients with type 2 diabetes in Isfahan, Iran. Diabetes Metab Res Rev. 2009;25(8):748–55.CrossRefPubMed
27.
Baldassarre D, Veglia F, Hamsten A, Humphries SE, Rauramaa R, De Faire U, et al. Progression of carotid intima media thickness as predictor of vascular events: results from IMPROVE Study. Arterioscler Thromb Vasc Biol. 2013;33:2273–9.CrossRefPubMed
28.
Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, et. al. Carotid intima media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT Collaboration. Diabetes Care 2015;38:1921-1929.
Metadata
Title
Evaluation of progression in metabolic parameters along with markers of subclinical inflammation and atherosclerosis among normoglycemic first degree relatives of type 2 diabetes mellitus patients
Authors
Deepak Kumar Dash
Swayamsidha Mangaraj
Arun Kumar Choudhury
Mamta Singh
Anoj Kumar Baliarsinha
Publication date
02-08-2022
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2023
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-022-01120-0

Other articles of this Issue 3/2023

International Journal of Diabetes in Developing Countries 3/2023 Go to the issue

Original Article

ECW/TBW is increased in type 1 diabetes mellitus patients with diabetic peripheral neuropathy: a retrospective case-control study

Review Article

A systematic review on foot muscle atrophy in patients with diabetes mellitus

Original Article

Innovative mobile-health led participatory approach to comprehensive screening and treatment of diabetes (IMPACT diabetes): rationale, design, and baseline characteristics

Original Article

Serum glucose, a cost-effective alternate of plasma glucose in diagnosing and monitoring diabetes mellitus

Original Article

Value of neutrophil/lymphocyte ratio in the diagnosis of diabetic neuropathy

Letter to the Editor

Nerve conduction study abnormalities in Indian children with type 1 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits